Edward Hæggström
CEO, Nanoform
A former Harvard professor with an academic portfolio consisting of over 400 papers and 25 patents/patent applications, Edward Hæggström co-founded Nanoform in 2015 to focus on nanoparticle engineering technology for small-molecule APIs. The company’s CESS technology was recently leveraged by Portuguese biotech company TargTex for a glioblastoma treatment study – and showed promising results.
We asked…
What inspired you to work in drug development?
I was intrigued by the fact that size, a physical attribute, can be used to modulate biochemical response relevant to medicines. Our aim at Nanoform is to touch the lives of a billion patients. We look forward to seeing what nanoformulations can do to improve health and wellbeing.
Tell us about the most important project you’ve worked on to date…
Nanoform is my most intriguing project and I hope it will become important to many people.
Make a prediction for the far flung future of the industry that may seem like science fiction but could one day be a reality…
I have publicly stated that Nanoform will try to double the number of medicines that reach the market each year, with the same R&D expenditure. I was inspired by the tricorder in Star Trek and I like the idea of going where other people have not gone before.
